Revelation Biosciences, Inc. (REVB)

NCM – Цена в реальном времени. Валюта: USD

1.04

+0.06 (6.31%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.02

-0.02 (-1.88%)

До открытия: May 13, 2026, 7:21 AM EDT

11.05.2026

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, released its 2026 annual meeting proxy materials today, which included a corporate update letter to its stockholders from James Rolke, Chief Executive Officer of Revelation, the body of the letter follows. Dear Stockholders: As you know, Revelation is a clinical stage company working to develop a high-impact, potentially lifesaving drug called Gemini for the treatment of acute kidney injury (AKI).

07.05.2026

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026. Corporate Highlights Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury Received net proceeds of $6.7 million from warrant inducement in January 2026 Participated in a fireside chat at the 38th Annual ROTH Conference, during which management discussed the Company's developments and strategic priorities Presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026) Initiated discussions with potential clinical research organizations for the single adaptive Phase 2/3 study "The incredible momentum achieved in 2025 is continuing in 2026," said James Rolke, Chief Executive Officer of Revelation.

06.04.2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced formation of an Acute Kidney Injury (AKI) Advisory Board for the upcoming Phase 2/3 AKI clinical trial. This distinguished panel brings together internationally recognized Nephrologists and Critical Care Physicians who will guide the company's clinical strategy, monitor progress, and ensure the initiative achieves the goal of improving patient care by advancing Gemini for the treatment of AKI.

30.03.2026

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on innovative solutions for acute and chronic disease, presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026). Presented datademonstrated the capability of Gemini to normalize the hyperinflammatory state and restore immunocompetence up to 7 days after a single dose, in stage 3 and 4 chronic kidney disease (CKD) patients peripheral blood mononuclear cells.

24.03.2026

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced a reminder of its participation in a fireside chat on Tuesday, March 24, 2026, at 2:00 p.m. PT, as part of the 38th Annual Roth Conference, in Dana Point, CA.

19.03.2026

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, announced today that James Rolke, Revelation's Chief Executive Officer, and Chester S. Zygmont, III, Revelation's Chief Financial Officer, will be attending the 38th Annual Roth Conference, in Dana Point, CA, on Monday and Tuesday March 23rd and 24th.

26.02.2026

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025. Corporate Highlights Announced Positive Results from PRIME Clinical Study in late-stage chronic kidney disease patients Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury Received net proceeds of $6.7 million from warrant inducement in January 2026 Clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology in San Diego (March 29 - April 1, 2026) "2025 was a positive year for Revelation with significant advancement of the Gemini program," said James Rolke, Chief Executive Officer of Revelation.

Видео

No Data

There is no data to display

Пресс-релизы

11.05.2026

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

07.05.2026

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

06.04.2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

30.03.2026

Revelation Biosciences, Inc. (REVB)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Revelation Biosciences, Inc. (REVB)

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

Видео

No Data

Пресс-релизы

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

Видео

No Data

Пресс-релизы

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

Search stocks

Revelation Biosciences, Inc. (REVB)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Revelation Biosciences, Inc. (REVB)

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

Видео

No Data

Пресс-релизы

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

Видео

No Data

Пресс-релизы

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study